Literature DB >> 7517673

Antisense src expression inhibits proliferation and erythropoietin-induced erythroid differentiation of K562 human leukemia cells.

A Kitanaka1, M Waki, H Kamano, T Tanaka, Y Kubota, H Ohnishi, J Takahara, S Irino.   

Abstract

We constructed a recombinant plasmid which expresses antisense src RNA in human cells and used it as a tool for investigating the role of pp60c-src in proliferation and differentiation of K562 human leukemia cells. In erythropoietin (EPO)-responsive cells, EPO induces rapid tyrosine phosphorylation of several cellular proteins including EPO receptor (EPOR) although EPOR has no tyrosine kinase domain. Here we show that antisense src RNA expression suppresses pp60c-src synthesis in the recombinant plasmid-transfected K562 cells, reduces the proliferation and inhibits hemoglobin synthesis and glycophorin A expression promoted by EPO in K562 cells. These findings suggest that pp60c-src plays crucial roles in the proliferation and EPO-induced erythroid differentiation of K562 cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7517673     DOI: 10.1006/bbrc.1994.1878

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Involvement of Gialpha2 in sodium butyrate-induced erythroblastic differentiation of K562 cells.

Authors:  M G Davis; Y Kawai; I J Arinze
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

2.  Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3-kinase.

Authors:  Y Kubota; T Tanaka; A Kitanaka; H Ohnishi; Y Okutani; M Waki; T Ishida; H Kamano
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

3.  The Downregulation of Both Giant HERCs, HERC1 and HERC2, Is an Unambiguous Feature of Chronic Myeloid Leukemia, and HERC1 Levels Are Associated with Leukemic Cell Differentiation.

Authors:  Muhammad Shahzad Ali; Stefano Magnati; Cristina Panuzzo; Daniela Cilloni; Giuseppe Saglio; Barbara Pergolizzi; Enrico Bracco
Journal:  J Clin Med       Date:  2022-01-10       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.